Preclinical efficacy & intermediate endpoint biomarkers IDIQ contract in support of the prevent cancer preclinical drug development program
Active Awarded Last action
- Contract number
- 75N91024D00005
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 3 $3,142,485 obligated
Award facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Combined order value
-
- $3,142,485 Current, with exercised options
- $4,268,745 Potential, with all options
- Last date to order 55% complete
- IDV ceiling 2% used
- $149,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded an indefinite delivery contract to University Of Oklahoma Health Sciences Center on January 25, 2024, with a ceiling of $149,995,000 and an ultimate completion date of January 24, 2029. This is a multiple-award vehicle with no set-aside.
Place of performance is Oklahoma City, Oklahoma. The IDIQ procures preclinical drug development research, including evaluation of efficacy and pharmacodynamic biomarkers for potential cancer preventive agents in support of the PREVENT Cancer Preclinical Drug Development Program.
The originating pre-solicitation was posted December 19, 2022, with a due date of February 6, 2023. Delivery orders issued under this IDIQ include a $1,886,811.80 firm fixed price order awarded June 17, 2024, for development of a novel multivalent mRNA vaccine targeting triple-negative breast cancer, with ultimate completion June 16, 2026, and a $1,234,179 firm fixed price order awarded September 25, 2025, for further development of mitochondria-targeted honokiol for prevention of lung cancer adenocarcinoma and squamous cell carcinoma, with ultimate completion March 24, 2028. Both orders are performed in Oklahoma City.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| The Methodist Hospital Research Institute | $1,122,335 | |
| The Methodist Hospital | $693,916 |
Quick answers
Who was awarded contract 75N91024D00005?
75N91024D00005 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on January 25, 2024.
How much is contract 75N91024D00005 worth?
Orders under 75N91024D00005 have obligated $3,142,485. Their combined potential value, with all options, is $4,268,745. 75N91024D00005's own ceiling is $149,995,000.
How many orders have been placed under contract 75N91024D00005?
3 orders have been placed under 75N91024D00005, the latest on September 14, 2026.
Who can order from contract 75N91024D00005?
75N91024D00005 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91024D00005 part of a contract vehicle?
Yes. 75N91024D00005 is part of PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024D00005 competed?
The extent of competition for 75N91024D00005 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV